provider portal
GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark Approval for GLP-1 Therapy How GLP-1's Address OSA in Healthcare Technology Potential Side Effects and Safety Warnings Wesper’s Role in Emerging OSA Treatments FDA’s Landmark Approval for GLP-1 TherapyOn December 20, 2024, the Food and Drug Administration (FDA’s official press announcement) recognized a major milestone by approving Zepbound (tirzepatide) for adults with moderate to severe obstructive sleep apnea. According to Dr....
Featured Articles
In primary care, the integration of...
READ
Wesper is poised to change sleep...
READ
the WESPER JOURNAL
Discover Our
Clinical Validations
Wesper’s technology is backed by rigorous clinical validations, ensuring accuracy and reliability in sleep health monitoring. Tested against gold-standard sleep studies, Wesper delivers precise data on sleep quality, stages, snoring, and breathing patterns, providing both patients and providers with trusted insights for effective sleep management.
GETTING TO KNOW OUR SLEEP EXPERT
Questions? Dr. Rohrscheib has Answers.
Struggling with undiagnosed sleep apnea? You’ve come to the right place. Dr. Chelsie Rohrscheib, our in-house sleep expert and researcher, provides valuable educational content on conditions associated with sleep apnea and how Wesper can offer solutions to help you take control of your sleep health.
Watch our youtube shorts now